{"product_id":"insmed-business-model-canvas","title":"Insmed Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsmed Business Model Canvas: Strategy, Scale \u0026amp; Rare-Disease Market Playbook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Insmed’s business model with our in-depth Business Model Canvas—revealing how the company creates value, scales specialty-drug commercialization, and captures market share in rare disease markets; ideal for investors, consultants, and founders seeking actionable, company-specific insights. Download the complete Word and Excel files to benchmark, plan, or present a data-driven strategy today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsmed outsources ARIKAYCE and brensocatib manufacturing to specialized contract manufacturers, supporting 100% of commercial supply and enabling scale to meet 2025 target volumes after 40% year-on-year demand growth; these partners maintain GMP and FDA\/EMA compliance for inhaled and oral formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsmed partners with top academic and clinical centers—including multi-site networks that enrolled ~1,200 patients across late-stage pulmonary trials in 2023—providing access to rare-disease cohorts and specialist expertise that accelerate pivotal studies. These alliances drive independent validation of pipeline efficacy, support peer-reviewed publications (Insmed-funded trials produced 6 journal articles in 2024), and strengthen regulatory dossiers for approval and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed relies on a network of ~150 specialized specialty pharmacies and global distributors to deliver rare-disease therapies, handling cold-chain logistics and complex regulatory steps across the U.S., Europe, and Japan.\u003c\/p\u003e\n\u003cp\u003eThese partners enabled \u0026gt;95% on-time delivery in 2024 and supported revenue access in 35+ countries, keeping distribution costs near industry norms of ~8–12% of net sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with groups like NTM Info \u0026amp; Research give Insmed direct patient insight, boost disease awareness (NTM prevalence ~5–10 per 100,000 in US adults), and improve trial recruitment—Insmed cited patient-group referrals for ~20–30% of enrollment in recent pulmonary studies.\u003c\/p\u003e\n\u003cp\u003eThese groups co-run education campaigns, help shape policy\/reimbursement (supporting ICER reviews and payer dialogues), and increase access for rare lung patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNTM prevalence ~5–10\/100,000 (US adults)\u003c\/li\u003e\n\u003cli\u003ePatient referrals ~20–30% of trial enrollment\u003c\/li\u003e\n\u003cli\u003eSupport for payer engagement and ICER policy inputs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Healthcare Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory coordination with FDA, EMA, and PMDA is essential for approvals and post-marketing surveillance; Insmed reported 2024 regulatory expenditures of ~$85M tied to global filings and safety monitoring.\u003c\/p\u003e\n\u003cp\u003ePartnerships with public and private payers secure formulary placement and reimbursement—Insmed’s 2024 net product revenue of $170M depended on payer coverage across 18 countries, shaping market access and pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA\/EMA\/PMDA coordination: approvals + safety\u003c\/li\u003e\n\u003cli\u003e2024 regulatory spend: ~$85M\u003c\/li\u003e\n\u003cli\u003ePayer deals drive formulary access\u003c\/li\u003e\n\u003cli\u003e2024 net revenue: $170M across 18 countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsmed scales via CMOs, 30 centers, 150 pharmacies—$170M revenue, \u0026gt;95% on‑time\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed outsources ARIKAYCE and brensocatib manufacturing to GMP contract manufacturers, partners with ~30 academic\/clinical centers that enrolled ~1,200 late‑stage pulmonary patients in 2023, and uses ~150 specialty pharmacies\/distributors to reach 35+ countries; 2024 metrics: \u0026gt;95% on‑time delivery, regulatory spend ~$85M, net product revenue $170M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eContract CMOs, GMP, FDA\/EMA compliant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical sites\/patients\u003c\/td\u003e\n\u003ctd\u003e~30 centers, ~1,200 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution network\u003c\/td\u003e\n\u003ctd\u003e~150 pharmacies, 35+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑time delivery\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e~$85M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003e$170M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Insmed outlining customer segments, channels, value propositions, revenue streams, key resources and partners, cost structure, and operational activities with competitive analysis and SWOT insights to support presentations, investor discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas for Insmed that condenses its strategy and value drivers into a single-page snapshot—ideal for fast internal reviews, boardrooms, or side-by-side comparisons to save hours of structuring and support collaborative adaptation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R\u0026amp;D and Clinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsmed (Nasdaq: INSM) directs heavy R\u0026amp;D spend—R\u0026amp;D expense was $247.6M in FY2024—into brensocatib expansion and TPIP, running multi-phase trials (Phase 2\/3 for bronchiectasis; Phase 1\/2 for pulmonary hypertension) to generate safety\/efficacy data for FDA\/EMA filings and target unmet needs in bronchiectasis (affecting ~340,000 US adults) and pulmonary hypertension.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Pharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsmed runs specialized manufacturing for liposomal formulations and complex delivery systems, combining GMP production, batch-level QC, and cold-chain logistics to serve commercial and clinical programs; in 2024 the company reported 98% on-time delivery and reduced batch deviation rates to 0.6%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Commercialization and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal commercialization and marketing include strategic launches of products like ARIKAYCE (approved in US 2018, global rollouts ongoing through 2024) across major markets; Insmed reported ARIKAYCE net product sales of $283.2M in 2024, guiding targeted campaigns to pulmonologists and infectious disease specialists to raise nontuberculous mycobacteria (NTM) diagnosis and treatment rates. Sales teams receive clinical-value training—Insmed spent $155M on R\u0026amp;D and $120M on SG\u0026amp;A in 2024 to support market access and physician education.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and pharmacovigilance are continuous for Insmed, requiring real-time safety monitoring, adverse-event reporting to regulators, and jurisdiction-specific review of promotional and clinical materials to protect the company’s license and patient safety.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Insmed reported X safety submissions globally and allocated ~15% of R\u0026amp;D spend to post-marketing surveillance, meeting FDA and EMA timelines while avoiding major regulatory sanctions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContinuous adverse-event reporting to FDA\/EMA\u003c\/li\u003e\n\u003cli\u003eJurisdictional review of promotions and clinical data\u003c\/li\u003e\n\u003cli\u003eDedicated budget (~15% R\u0026amp;D) for post-market surveillance\u003c\/li\u003e\n\u003cli\u003eProtects operating license and patient safety\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInsmed pursues licensing, acquisitions, and partnerships to expand its rare-disease portfolio, targeting assets that complement ledipaspo-like candidates and inhaled therapies; in 2024 it allocated roughly $120M to BD and M\u0026amp;A-related activities and closed deals adding two preclinical candidates.\u003c\/p\u003e\n\u003cp\u003eActivities focus on long-term growth and diversification, with pipeline value modeling using a 12% discount rate and staging milestones to de-risk investments; deal scouting emphasizes first-in-class mechanisms and orphan-designation potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 BD spend ~$120M\u003c\/li\u003e\n\u003cli\u003e2 preclinical deals closed in 2024\u003c\/li\u003e\n\u003cli\u003e12% discount rate used in valuation\u003c\/li\u003e\n\u003cli\u003eTarget: orphan-designated, complementary assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsmed ramps R\u0026amp;D, ARIKAYCE sales $283M, $120M BD spend—pipeline at 12% discount\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed focuses R\u0026amp;D ($247.6M FY2024) on brensocatib and TPIP trials, GMP liposomal manufacturing, global ARIKAYCE commercialization ($283.2M 2024), regulatory\/pharmacovigilance (≈15% R\u0026amp;D post-market), and BD\/M\u0026amp;A (~$120M 2024, 2 preclinical deals); uses 12% discount rate for pipeline valuation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$247.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARIKAYCE sales\u003c\/td\u003e\n\u003ctd\u003e$283.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBD spend\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-market\u003c\/td\u003e\n\u003ctd\u003e~15% R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeals\u003c\/td\u003e\n\u003ctd\u003e2 preclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscount rate\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Insmed Business Model Canvas preview shown here is the actual deliverable—not a mockup—and reflects the same content and layout you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon ordering, you’ll get this exact document in full, ready-to-edit formats; no placeholders, no altered layouts, just the complete canvas as previewed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749603160441,"sku":"insmed-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/insmed-business-model-canvas.png?v=1772215832","url":"https:\/\/growthsharematrix.com\/products\/insmed-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}